单次大剂量肝区放射照射治疗原发性肝癌肝区疼痛患者效果研究*

doi:10.3969/j.issn.1672-5069.2023.02.030

Abstract

Abstract: Objective The aim of this study was to investigate the effect of single high dose of hepatic irradiation on amelioration of hepatic pain in patients with primary liver cancer (PLC). Methods 76 patients with PLC and hepatic pain were encountered in our hospital between June 2018 and June 2021, and were divided randomly into observation and control group, with 38 cases in each group. All the patients received supporting treatment, and those in the observation group received a single dose of large dose of liver irradiation. The brief pain inventory (BPI) and the European organization for research and treatment of cancer (EORTCQLQ-C30) score were evaluated. Results One month after enrollment, the BPI score in irradiation-treated patients was (1.7±0.8), significantly lower than [(3.4±1.3), P＜0.05] in the control; the functional and overall health status/quality of life aspects by the EORTCQLQ-C30 were(47.2±7.0) and (12.7±1.2), both significantly higher than [(35.6±6.0) and (8.6±0.8), respectively, P＜0.05], while the symptom and single measurement item scores were (10.2±2.2) and (15.4±3.1), significantly lower than [(18.1±5.0) and (19.6±4.2), respectively, P＜0.05] in the control group; the common symptoms after irradiation were nausea and vomiting, fatigue and anorexia in 24 cases(63.2%), fever in 8 cases (21.1%), upper gastrointestinal bleeding in 9 cases (23.7%) and leucopenia in 3 cases(7.0%), which were ameliorated gradually after in time management; at the end of 60 day followed-up, the fatality rate in the irradiation-treated group was 44.7%, and that in the control was 55.3%, not significantly different by Kaplan-Meier analysis (Log-Rank=0.497, P=0.481). Conclusion A single high-dose of hepatic irradiation in patients with PLC and liver pain could gain a good therapeutic relieve pain effect and relatively improve the quality of life in this circumstance.

Key words: Hepatoma, Liver pain, Radiation therapy, Quality of life

Gu Kai, Wu Xiaochen, Zhu Yiming. Single high dose of hepatic irradiation in ameliorating hepatic pain in patients with primary liver cancer[J]. Journal of Practical Hepatology, 2023, 26(2): 270-273.

References

[1] Malki A, El-Sharkawy A, Mohamed M, et al. Antitumor activities of the novel isosteviol derivative 10c against liver cancer. Anticancer Res, 2017, 37(4): 1591-1601.
[2] Shah B K, Kandel P, Khanal A. Second primary malignancies in hepatocellular cancer - a US population-based study. Anticancer Res, 2016, 36(7): 3511-3514.
[3] Yamaguchi H, Kuroda K, Sugitani M, et al. Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. Int J Oncol, 2017, 50(5): 1749-1759.
[4] Pietrantonio F, Cotsoglou C, Fucà G, et al. Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases. Clin Colorect Cancer, 2019, 18(1): 34-43.
[5] Zhou JX, Li XL. Association of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy. Oncol Lett, 2018, 16(5): 6633-6637.
[6] Venkat P S, Hoffe S E, Frakes J M. Stereotactic body radiation therapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control, 2017, 24(3): 1-6.
[7] Wu Z F, Zhang J Y, Shen X Y, et al. A mouse radiation-induced liver disease model for stereotactic body radiation therapy validated in patients with hepatocellular carcinoma. Med Phys, 2016, 43(7): 4349-4361.
[8] Aliberti C, Carandina R, Sarti D, et al. Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. Anticancer Res, 2016, 36(7): 3515-3521.
[9] Napoletano C, Taurino F, Biffoni M, et al. Rfa strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol, 2008, 32(2): 481-490.
[10] 傅思睿, 陆骊工. 索拉菲尼在肝癌靶向治疗中的应用. 中华医学杂志, 2012, 92(29): 2084-2086.
[11] Yin Z, Jiang K, Li R, et al. Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy. Mol Cancer, 2018, 17(1): 178-178.
[12] Tong D, Wu L, Chen X, et al. Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice. Eur J Cancer Care, 2018, 27(4): 1-6.
[13] Soliman H, Ringash J, Jiang H, et al. Phase ii trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol, 2013, 31(31): 3980-3986.
[14] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6): 929-946.
[15] 閤谦, 吴骋, 童林军, 等. RECIST1. 1、PERCIST1. 0、WHO及EORTC用于评价结直肠癌肝脏转移化疗后疗效的比较. 中华核医学与分子影像杂志, 2017, 37(9): 559-563.
[16] 张晓玲, 翟丽萍, 官俏兵, 等. 老年帕金森病伴疼痛患者的临床特征. 中华老年医学杂志, 2016, 35(2): 159-162.
[17] Montazeri A, Harirchi I, Vahdani M, et al. The European organization for research and treatment of cancer quality of life questionnaire (eortc qlq-c30): Translation and validation study of the Iranian version. Support Care Cancer, 1999, 7(6): 400-406.
[18] Bernstein M B, Krishnan S, Hodge J W, et al. Immunotherapy and stereotactic ablative radiotherapy (isabr): A curative approach? Nat Rev Clin Oncol, 2016, 13(8): 516-524.
[19] Goblirsch M, Lynch C, Mathews W, et al. Radiation treatment decreases bone cancer pain through direct effect on tumor cells. Radiat Res, 2005, 164(4): 400-408.
[20] Lutz S T, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol, 2014, 32(26): 2913-2919.

Single high dose of hepatic irradiation in ameliorating hepatic pain in patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gong Cheng, Tian Yinsheng, Liu Shuang. Comparison of two-year survivals in primary liver cancer patients with spontaneous tumor rupture underwent hepatectomy at early or late operation time windows [J]. Journal of Practical Hepatology, 2023, 26(2): 274-277.
[2]	Shi Hao, Chen Yong, Luo Bin, et al.. Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 278-281.
[3]	Jiang Huizhen, Chen Jun, Chen Chunmei, et al. Performance of quantitative parameters by dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of benign and malignant hepatic space-occupying lesions [J]. Journal of Practical Hepatology, 2023, 26(1): 100-103.
[4]	Gao Xiangrui, Liu Hongyan, Zhang Huai, et al. Differential diagnosis of hepatic hemangioma and hepatocellular carcinoma by multi-b-value diffusion-weighted imaging of high-field magnetic resonance [J]. Journal of Practical Hepatology, 2023, 26(1): 104-107.
[5]	Ding Haibin, Zhang Xin, Li Ya, et al. TACE with sequential microwave ablation followed by oral sorafenib maintenance in treatment of patients with large hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2023, 26(1): 108-111.
[6]	Peng Yu, Li Haitao, Yang Wenli, et al. Clinical efficacy of PD-1 inhibitor and lenvatinib in the treatment of elderly patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(1): 112-115.
[7]	Du Shangyun, Weng Li, Wu Min. Clinical observation of camrelizumab therapy after TACE in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(1): 116-119.
[8]	Zhang Zixia, Li Delin, Zhang Guoliang. Clinical efficacy of Yipi Yanggan Decoction after radiofrequency ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(1): 142-144.
[9]	He Xiaojin, Li Dan, Zhou Qing, et al.. Expression of hepatitis B virus X protein and suppressor of cytokine signaling-1 in L02 cells in vitro [J]. Journal of Practical Hepatology, 2022, 25(6): 772-775.
[10]	Zhang Yaohui, Zheng Zhangzeng, Gao Xing, et al.. Contrast-enhanced ultrasound time-intensity curve in assessment of liver nodules in cirrhotic patients [J]. Journal of Practical Hepatology, 2022, 25(6): 861-864.
[11]	Mao Yueqin, Zhang Hongxia, Song Haiyan, et al.. Clinical efficacy of auxiliary DutanyuPixu Formulae therapy after TACE in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(6): 873-876.
[12]	Wu Zhenghong, Wu Dongqiu, Liu Sibin. Performance of DCE-MRI in diagnosis and evaluation of TACE efficacy in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(6): 881-884.
[13]	Lan Sirong, Xu Jiwei, Zhang Yaoming, et al.. Guidance of real-time contrast-enhanced ultrasonography and 3D ultrasound fusion imaging for ablation area in patients with primary liver cancer during microwave ablation therapy [J]. Journal of Practical Hepatology, 2022, 25(6): 889-892.
[14]	Li Ji, Zhou Zhongsong, Gao Yufeng, et al.. Short-term clinical efficacy of microwave ablation under the guidance of ultrasound fusion imaging in the treatment of patients with small primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(5): 698-701.
[15]	Fan Shunke, Wang Guiluo,Yi Xiaoyan. Different dosage of sevoflurane and propofol combination venous-inhalation anesthesia in patients with primary liver cancer undergoing radical hepatectomy [J]. Journal of Practical Hepatology, 2022, 25(5): 702-705.